

# CELL BIOTECH

---

Probiotics & Microbiome company



## 2025 4Q Earnings Release

2026. 04.

As a note, it is suggested to use this material only as a reference, as it contains information and data that are subject to changes without prior notice due to the external audit process, and may cause the actual results to differ from those stated or implied in this material.

# 4q Earnings Summary

Revenue up 20.3% to KRW 14.6 billion, operating profit up 30.5% to KRW 3.0 billion

Domestic revenue down -0.1%, overseas revenue up 40.3%

Duolac brand sales up 2.9% to KRW 6.8 billion, OEM/ODM sales up 63% to KRW 6.7 billion, Raw material sales down -20.7% to KRW 1.1 billion

(unit : KRW 100 mil)


	2024 4q	% of revenue	2025 4q	% of revenue	YoY(%)
Revenue	121.6		146.3		20.3
Domestic	60.2	49.5	60.15	41.1	-0.1
Overseas	61.4	50.5	86.15	58.9	40.3
	2024 4q	Profit margin (%)	2025 4q	Profit margin (%)	YoY(%)
Operating profit	11.3	9.3	30.5	20.8	169.9
Net Profit	68.6	56.4	38.4	26.2	-44.0

# Revenue trends

4q revenue KRW 14.6 billion, yoy +20.3%, qoq -4.7%


## Quarterly revenue

(unit : KRW mil)



## Full year revenue

(unit : KRW mil)




# Profit trends

4q operating profit KRW 3.0 billion, yoy + 170%  
 Net Profit KRW + 3.8 bil.


## Quarterly profit

(unit : KRW mil)




## Full year profit

(unit : KRW mil)



# Revenue breakdown

4q revenue of Duolac brand + 2.9% to 6.9 KRW bil., OEM/ODM + 63% to 6.6 KRW bil., and raw material -20.7% to 1.1 KRW bil.



## Microbiome R&D

- 1) Microbiome First-in-Class anticancer pipeline 'PP-P8' clinical phase 1 IND submitted (Mar 5, 2021)
- 2) Acquisition European patent of PP-P8 (Apr 1, 2021) (patent number EP3453718)
- 3) Acquired US patent for Probiotics drug delivery system (22. 12. 20)
- 4) P8 anticancer mechanism paper MOA (23.06.07)  
Anti-Cancer Roles of Probiotic-Derived P8 Protein in Colorectal Cancer Cell Line DLD-1, Int. J. Mol. Sci, 2023
- 5) Cellbiotech, Colorectal Cancer Drug Phase 1 Clinical Trial Plan Approved by Korea MFDS (Mar 20, 2024)
- 6) Cellbiotech starts phase 1 of microbiome colorectal cancer drug 'PP-P8'

<https://www.hankyung.com/article/202502194939i>

No. 1 in global export for 12 consecutive years

- 1) Cellbiotech's probiotics 'DUOLAC' ranked No. 1 in the world for 12 consecutive years



<https://www.mk.co.kr/en/it/11341049>

## FDA GRAS World's Most Listed

1) Cellbiotech "11 types of lactic acid bacteria secured FDA GRAS certification... The World's Largest Holdings"



<https://www.hankyung.com/article/202402222016i>

2) Cellbiotech, Probiotics Leading... Global Leap



<https://www.dailypharm.com/Users/News/NewsView.html?ID=309331&REFERER=NP>

“Now is the Era of K-Probiotics”

– Cellbiotech’s ‘Duolac’ Achieves No. 1 Market Share in Denmark, the Home Country

1) Surpassing Local Brand ‘Lactocare’ --- Assuming the Top Spot with a 46.6% Market Share



<https://n.news.naver.com/mnews/article/016/0002614577?sid=101>

# Consolidated Financial Summary

CELL BIOTECH

## Income statement

(unit : KRW 100 mil., %)

	2024 4q		2025 4q	
	Amount	Ratio	Amount	Ratio
Revenue	121.6	100.0	146.3	100.0
Gross profit	88.5	72.8	107.1	73.2
SG&A expenses	77.2	63.5	76.6	52.3
Operating profit	11.3	9.3	30.5	20.9
Consolidated net income	68.6	56.4	38.4	26.2

## Statement of financial position

(unit : KRW 100 mil., %)

	2024 .12	2025 4q
Assets	1,304	1,366
Current Assets	971.48	1,037
Non current Assets	332.49	329
Liabilities	62.28	49
Current Liabilities	58.62	49
Non current Liabilities	3.66	1
Shareholder's Equity	1,242	1,316